Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Congress and Expo on Optometry and Vision Science
(10 Plenary Forums - 1Event) Chicago,USA.

Day 1 :

OMICS International World Optometry 2017 International Conference Keynote Speaker Rolando Toyos photo

Rolando Toyos is an American Physician and Medical Director who specializes in Ophthalmology. He developed the use of intense pulsed light for the treatment of dry eye conditions such as meibomian gland dysfunction.


Introduction: This project was undertaken to assess the clinical value of using a new transscleral cyclophotocoagulation device in patients with mild to severe glaucoma including those who have unsuccessfully undergone other procedures. This is a one year update of earlier reported data.


Method: This is a single site review of 26 eyes of 20 patients, 4 eyes were classified as mild glaucoma, 5 as moderate and 18 as severe or end stage glaucoma. Two eyes of one patient were lost to follow up. All eyes but 3 had previously undergone phacoemulsification and SLT or MLT. 4 eyes had previously undergone trabeculectomy.


Results: Patients undergoing the procedure had an average IOP of 25.6 and were on an average of 3 IOP lowering meds. After the procedure, patients were started on difluprednate hourly for the first day then tapered over 3 weeks. Average IOP drop at POD 1 was 20% and 34% at pod7 (using an average 1.3 IOP lowering meds). At POD14, average IOP from baseline was 8% using one IOP lowering medication. At one month, IOP was down by 20% and average number of IOP reducing medications was 1.2. At 6-12 months, the average IOP lowering was 30% compared with baseline IOP on and average of 1.8 medications. There were no serious adverse events.


Conclusion: Patients with glaucoma of varying severities are able to safely undergo transscleral cyclophotocoagulation. On average, IOPs were reduced by 30% over one years’ time and number of IOP lowering medications was reduced by 60%. Further study is required to determine ideal treatment guidelines.

OMICS International World Optometry 2017 International Conference Keynote Speaker Hugo Quiroz Mercado photo

Hugo Quiroz-Mercado is an Ophthalmologist specializing in Diabetic Retinopathy and Retinopathy Prematurity as the Director of Ophthalmology Service at Hugo Quiroz-Mercado. With over 25 years of practice experience, he has held previous appointments as the Director of the Retina Department and Chief of the Experimental Surgery Laboratory at Luis Sanchez Hospital for the Prevention of Blindness, as well as Professor of Ophthalmology at the Facultad de Medicine Universidad Autonoma de Mexico.


Researchers have long known that integrins serve as “bridges” between cells and regulate how cells interact with each other and with the extracellular matrix. There are 27 known integrins, each named for a specific alpha-beta combination. Integrins have been associated with angiogenesis, inflammation, and thrombosis, so it makes sense to investigate them as potential treatments for ocular disorders. However, finding agents that can inhibit integrins has been challenging. One integrin antagonist, lifitegrast (Xiidra, Shire), recently received US Food and Drug Administration approval for the treatment of dry eye. ALG-1001 (Luminate, Allegro Ophthalmics) has the potential to target four different integrin sites. This agent has two mechanisms of action. First, it inhibits three integrins considered to be angiogenic; angiogenesis is a key factor in AMD, DME, and RVO. Integrins are known to work both upstream and downstream of the VEGF pathway. Second, ALG-1001 inhibits an integrin-mediated pathway of the vitreoretinal interface, making it capable of inducing posterior vitreous detachment (PVD).


Anti-edematous Effect: ALG-1001 seems to have clear anti-edematous and antiproliferative effects. Its mechanism is quite different from that of anti-VEGF agents; therefore, this compound has potential as both adjunctive and standalone therapy. It addresses the goal of using multiple therapeutic approaches with different mechanisms of action that target different aspects of disease. Because ALG-1001 inhibits multiple integrins, including αvβ3, αvβ5, and α5β1, it may be able to prevent new blood vessel formation while concurrently stopping leakage from existing blood vessels. Early study results have suggested that this combination of integrin inhibition may be potent enough to be used as monotherapy for DME and AMD. What is particularly interesting, however, is that these early data also suggest that anti-integrin therapy may be effective for patients who have not been successfully managed with anti-VEGF treatments alone. A phase 1 study of ALG-1001 in DME enrolled 15 patients with poor vision and substantial intraretinal fluid who had undergone more than 10 anti-VEGF injections. In this trial, eight of the 15 (53%) patients improved by 3 to 5 lines in visual acuity testing; four (50%) of these patients improved from legal blindness to functional vision in the range of 20/40 to 20/60. Additionally, more than half the patients in this phase 1 trial experienced a 30% to 80% reduction in central macular thickness. The substantial improvement seen in these patients has driven the ongoing investigation of ALG-1001 for treatment of DME.


Vitreolysis Effect: Vitreomacular traction (VMT) is a pathology associated with the vitreoretinal interface. In a normally aging eye, the vitreoretinal interface gradually releases. In eyes with VMT, although the rest of the vitreous is released from the retina, a residual area of adhesion remains. It is extremely difficult to effect that release without causing damage to the retina. From a pharmacologic standpoint, it has recently become possible to use an enzyme to achieve vitreomacular detachment, although surgical removal of the adhesion remains the standard of care. Inducing a posterior vitreous detachment (PVD) in a patient with a normal vitreoretinal interface can be viewed as assisting part of the spectrum of normal vitreous aging. There are numerous hypotheses about how the vitreous releases, and some suggest that overstimulating VEGF could create a depot of sorts at the vitreoretinal interface, possibly causing disease to progress. There is a significant body of evidence that suggests that inducing a PVD may inhibit the progression of retinal disease, particularly DR. We know that, in proliferative DR (PDR), blood vessels grow onto the vitreous scaffolding. But if the vitreous has undergone a PVD and elevated itself, there would be no scaffolding for vessels to grow onto. In theory, this could stop the proliferation from occurring. Or it might cause the growth to behave more like coral branching out from the seabed, doing little damage because it is not causing traction. In the phase 1 study of ALG-1001 in DME, researchers noted a high rate of PVD. Evidence suggests that ALG-1001 inhibits a fourth integrin—α3β1—and, by doing so, aids in the breakdown of vitreous and its separation from the retina. This separation should move the hypothesized VEGF depot away from the retina, which would, in theory, prevent further damage.


Phase 2 Studies: ALG-1001 is being evaluated in several ongoing studies. DEL MAR is a phase 2b study evaluating ALG-1001 as monotherapy, as well as in combination therapy with anti-VEGF agents, and as a treat-and-maintain therapy. According to the manufacturer, results are anticipated as early as Q4 2016. DEL MAR has enrolled almost 120 patients. Efficacy endpoints include mean change in visual acuity and central retinal thickness (as measured by optical coherence tomography) at weeks 16 and 20. The study is evaluating 1.0, 2.0, and 3.0 mg of ALG-1001 in comparison with bevacizumab (Avastin, Genentech). A second arm of the study is evaluating ALG-1001 as an adjunctive therapy after treatment with any anti-VEGF agent, and a third arm is evaluating ALG-1001 in combination with bevacizumab. The last two arms are enrolling an additional 75 patients. The PACIFIC study is another phase 2b trial, enrolling about 100 subjects with nonproliferative DR without PVD to evaluate ALG-1001 as a standalone therapy. The trial will assess whether induction of PVD can inhibit progression to PDR. The PACIFIC trial will evaluate four doses of ALG-1001: 1.0, 2.0, 3.0, and 4.0 mg, with balanced saline solution as a placebo. Results from PACIFIC are expected in the first half of 2017, according to the manufacturer. The main endpoint is PVD induction based on optical coherence tomography and/or B-scan ultrasound. Another prospective, randomized, double-masked phase 2b study evaluated ALG-1001 in patients with vitreomacular adhesion (VMA) and VMT. Topline results indicate that this study met its endpoint, with 50% of patients who received the highest dose of ALG-1001 achieving release of VMT or VMA by day 90, compared with 9.7% of those receiving saline solution as placebo (P =.0129). The study randomly assigned 106 patients to receive ALG-1001 2.0, 2.5 mg, 3.2 mg, or placebo. The drug was well tolerated, with no drug-related toxicity or inflammation noted with repeated injections.


Conclusions: It is hoped that the reporting of the full datasets of these studies will reinforce the concept that, although these are small studies, ALG-1001 appears to be effective in a significant subset of patients with AMD or DME. The larger VMT study seems to suggest that ALG-1001 can effect vitreous release in a significant subset of patients. ALG-1001 shows promising efficacy, with mechanisms of action that are distinct from those of anti-VEGF therapy. This gives hope that the compound may become a new weapon in our armamentarium that may be complementary or additive to anti-VEGF therapy. If the results from DEL MAR, PACIFIC, and other future studies confirm early findings, ALG-1001 may become a viable alternative approach to both pharmacologic vitreolysis and treatment of AMD, DME, and DR.